AZD6234
AstraZeneca's long-acting amylin analog — Phase 2 in obesity (2024) — part of AZ's entry into the GLP-1-adjacent obesity space alongside ECC5004; analogous in mechanism to cagrilintide.
A long-acting amylin analog peptide in Phase 2 development by AstraZeneca for obesity; mechanistically comparable to cagrilintide and petrelintide, targeting amylin receptors (hybrids of the calcitonin receptor with RAMP1/2/3) to drive satiety and slow gastric emptying independently of GLP-1 agonism.
Mechanism of action
Amylin receptor agonism (calcitonin receptor / RAMP1/2/3 heterodimers) — drives satiety via area postrema and hypothalamic circuits, slows gastric emptying, and suppresses postprandial glucagon. Intended for combination with GLP-1 RAs (the cagrisema / MariTide paradigm).
Primary uses
- Obesity (Phase 2)
Typical dosing
Phase 2 doses not publicly finalized.
Regulatory status
Not approved. Phase 2 in obesity initiated 2024.
Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What the studies show
AZD6234 is an AstraZeneca candidate for obesity and overweight, studied alone and combined with AZD9550. No paper on it is in PubMed yet; these are its registered trials.
Registry · 2023
First phase 1
Safety, tolerability, pharmacokinetics and pharmacodynamics in 104 healthy participants, completed in February 2026.
NCT06132841 · ClinicalTrials.gov record
Registry · 2023
With AZD9550
A phase 1/2 trial of AZD9550 alone and combined with AZD6234 in 166 people with overweight or obesity; active, not recruiting.
NCT06151964 · ClinicalTrials.gov record
Registry · 2025
Formulations
Relative bioavailability of different subcutaneous formulations in 19 healthy participants; active, not recruiting.
NCT07220954 · ClinicalTrials.gov record
Registry · 2025
A platform study in China
A multi-drug phase 2 platform study in Chinese participants with obesity or overweight; active, not recruiting.
NCT07017179 · ClinicalTrials.gov record
References
- [manufacturer] AstraZeneca pipeline page — AZD6234 Phase 2 amylin analog.
- [clinicaltrials] ClinicalTrials.gov — AZD6234 Phase 2 obesity study.
- [clinicaltrials] ClinicalTrials.gov NCT06132841: "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese" AstraZeneca. Phase 1, completed, November 2023 to February 2026 (primary completion), 104 participants. Registry record read October 2, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT06151964: "A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight" AstraZeneca. Phase 1, Phase 2, active not recruiting, September 2023 to January 2027 (primary completion), 166 participants. Registry record read October 2, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT07220954: "A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234" AstraZeneca. Phase 1, active not recruiting, November 2025 to September 2026 (primary completion), 19 participants. Registry record read October 2, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT07017179: "This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight" AstraZeneca. Phase 2, active not recruiting, May 2025 to October 2026 (primary completion), 16 participants. Registry record read October 2, 2026.
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.